99% Top Quality Peptides Lyophilized Powder Tirzepatide Fitness and Weight Loss CAS 2023788-19-2

Sales manager:Joanna
whatsapp：+8619133978924
Email:joanna@xtmingheng.com

sincerely look forward to your inquiries about our products.

Our company is a modern advanced enterprise specializing in production and exportation of APIs, Pharmaceutical intermediates, plant extracts etc. Our products are widely used in medicine, health care products, cosmetics, nutritional supplements and food additives areas. Our factory covers an area of 95 acres, the proposed construction of the plant will be GMP standards, the factory environment clean and tidy, rational layout, with large and medium-sized production workshop and repocessed shop. It is equipped with advanced equipment quality inspection and research center. Those products of both quality and technical content have reached the domestic advanced level. Since its establishment, the company has attached great importance to the team training and technical reform. Our modern production equipment guarantees for a fast and effective production with a superior degree of accuracy throughout the whole production line, everything is done in-house, processing, extraction, packaging and transportation of all links, ensuring maximum quality and efficiency. We are constantly research and development new ingredients and innovative new products, have earned the respect & Admiration from the worldwide customers. After years of continuous development, company has been accumulated rich experience in international trade and customer resources, established a stable customer base and perfect marketing service network. In addition, the company has established long-term technical cooperation with experts and professors from many universities and research institutes in the province

.

Tirzepatide      is a peptide-based medication that has garnered significant attention in the field of diabetes management. As a member of the glucagon-like peptide-1 (GLP-1) receptor agonist class, Tirzepatide offers a novel approach to addressing the complexities of type 2 diabetes mellitus (T2DM). This peptide-based therapy has demonstrated promising results in clinical trials,  showcasing its potential to revolutionize diabetes treatment.

  The therapeutic potential of Tirzepatide extends beyond glycemic control, with emerging evidence suggesting its utility in addressing comorbidities commonly associated with T2DM.  Preclinical studies have indicated potential benefits of Tirzepatide in preserving beta-cell function, reducing inflammation, and improving cardiovascular function, highlighting its broader impact on metabolic health. These findings underscore the transformative role of peptide-based therapies like Tirzepatide in reshaping the landscape of diabetes care.

  In clinical practice,  Tirzepatide 10mg is typically used once weekly,  allowing for sustained pharmacological activity and consistent glucose-lowering effects throughout the treatment period. The recommended starting dose and titration schedule may vary based on individual patient factors, including baseline glycemic control, renal function, and concomitant medications. Close monitoring of glycemic parameters and adherence to treatment guidelines are essential to optimize therapeutic outcomes and minimize the risk of adverse events.

 Product Function 

The addition of GIP which anatagonizes the central effects of GLP-1 to cause nausea is designed to improve tolerability and also allow for more aggressive dosing with increased systemic exposure. A recent post-hoc analysis showed significantly decreased NASH-related biomarkers and increased adiponectin in patients with T2DM

  The weight-reducing actions of the GIPR-GLP1R co-agonist tirzepatide.Considerable interest is focused on the mechanisms of action of tirzepatide, a highly effective GIPR-GLP1R co-agonist that produces superior reductions in HbA1c and body weight, relative to that achieved with 1 mg once weekly of semaglutide in people with T2D. The GIPR is expressed in multiple regions of the mouse and human brain, in subsets of neurons and glial cells, with some hypothalamic and hindbrain cells exhibiting co-expression of the GIPR and GLP1R. Chemogenetic activation of GIPR + cells in the mouse hypothalamus acutely reduced food intake; however, co-administration of exendin-4 did not produce an additive reduction of food intake when compared to either intervention alone.

  Therapy with tirzepatide, 5-15 mg once weekly produces 8-12% body weight reduction in people with T2D, prompting ongoing development of tirzepatide as a weight loss agent for people with overweight or obesity. The importance of GIP for the weight loss properties of tirzepatide in humans is uncertain; however, tirzepatide failed to reduce body weight in Glp1r−/- mice, implicating a dominant role for the GLP1R in the weight loss observed with this agent. Glucose-dependent insulinotropic polypeptide (GIP) has been shown to reduce the extent of aversive responses induced by GLP-1 in mice and rats and decrease nausea and vomiting in the shrew.

Product Application   

• 1.Helps slow food leaving your stomach
• 2.Helps prevent your liver from making too much sugar
• 3.Helps the pancreas produce more insul when your blood sugar levels are high
• 4.Can help control blood glucose
• 5.Can reduce hyperglycemia, especially after meals
• 6.Can reduce fasting insul and fasting glucose
• 7.Can reduce hemoglobin A1c
• 8.Can decrease appetite and caloric intake, while inhibiting weight gain
• 9.Has been shown to lower triglyceride levels and oxidative stress from high LDL
• 

• Items	Specification
  Appearance	White Powder
  Assay	≥98.0%
  Identification	Positive Reaction
  Related Substances	≤0.5%
  Water	≤0.5%
  Residue On Ignition	≤0.1%
  Chloride	≤0.014%
  Heavy Metals	≤20ppm

• Peptide Storage Guidelines: General Tips

  When storing peptides, remember to:
  • Store peptide in a cold, dry, dark place
  • Avoid repeated freezing and thawing of peptide
  • Avoid overexposure to the air
  • Avoid light exposure
  • Avoid storing peptides in solution long term
  • Aliquot peptide according to experimental requirements

• 
  
• 
• 
• 
•